Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study to Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac (Live Attenuated Rotavirus Vaccine) as a 3-dose Series in Healthy Infants Aged Between 6 Weeks and 8 Weeks in Vietnam

X
Trial Profile

An Open Label Study to Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac (Live Attenuated Rotavirus Vaccine) as a 3-dose Series in Healthy Infants Aged Between 6 Weeks and 8 Weeks in Vietnam

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ORV 116E (Primary)
  • Indications Rotavirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jan 2021 Status changed from recruiting to completed, as per results published in the Vaccine
    • 15 Jan 2021 Results published in the Vaccine
    • 21 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 May 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top